copyrightwmichaelscheld,md(編輯修改稿)
2024-11-23 03:39 本頁面
【文章內(nèi)容簡介】 NDA Pipeline。 “pink sheet”) ABT773 Afelimomab Tigecycline (vs 18 novel oncology agents) 12 IOM report, 2020 “Unfortunately, placency toward infections diseases in the 1960’s, overconfidence in existing antibiotics, and petition from highly profitable opportunities for pharmaceutical development and sale in other fields of medicine resulted in a lag in the production of new classes of antibodies. This occurred despite significant advances in the fundamental science that has fueled pharmaceutical innovation in many other areas” 13 IDSA Antimicrobial Availability Task Force Charge “Develop novel public policy to ensure a sustainable supply of safe and effective antimicrobial drugs to protect public health” 14 TASK FORCE MEMBERS John G. Bartlett, MD, Chair John Hopkins Univ. SOM Baltimore, MD
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號(hào)-1